Analysis of safety and efficacy of transoral endoscopic clip band ligation Anti-Reflux therapy(C-BLART) in the treatment of gastroesophageal reflux disease

doi:10.3877/cma.j.issn.2095-7157.2025.04.005

Abstract

Abstract:

Objective

To evaluate the efficacy and safety of clip band ligation anti-reflux therapy(C-BLART) in the treatment of gastroesophageal reflux disease (GERD).

Methods

A retrospective analysis was conducted on GERD patients who underwent C-BLART at the Gastroenterology Department (Endoscopy Center), China-Japan Union Hospital of Jilin University between February 2023 and December 2024.

Results

Twenty-one patients were enrolled, all of whom successfully received C-BLART with a mean operative time of (10.8 ± 6.2) minutes. Postoperative complications included localized inflammation in 1 patient (4.8%) and mild dysphagia in 2 patients (9.5%), all of which resolved with appropriate management.All 21 patients completed 3- and 6-month follow-up assessments.Significant reductions in Reflux Disease Questionnaire (RDQ), GERD-Health Related Quality of Life (GERD-HRQL), and GERD Questionnaire (GERD-Q) scores were observed in 20 patients (95.2%) (P<0.05), accompanied by symptom improvement and sustained remission after medication reduction/ discontinuation.Among 16 patients (76.2%) who completed extended 12-month follow-up, these therapeutic benefits persisted (P<0.05).

Conclusion

C-BLART demonstrates a favorable safety profile and stable mid term efficacy for GERD management, indicating promising clinical applicability.

Key words: Gastroesophageal reflux disease, Clip band ligation anti-reflux therapy, Endoscopic examination, Effectiveness, Safety

Xinran Tang, Yizhao Wang, Mingyan Liu, Lianjun Ma. Analysis of safety and efficacy of transoral endoscopic clip band ligation Anti-Reflux therapy(C-BLART) in the treatment of gastroesophageal reflux disease[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2025, 12(04): 246-251.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2025.04.005

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2025/V12/I04/246

Figures/Tables 6

References 21

[1]	吕昆明，王沙沙，万军，等．胃食管反流病与特发性肺纤维化关系的研究进展[J/OL]．中华胃肠内镜电子杂志，2023，10(2)：121-124.
[2]	Nirwan JS，Hasan SS，Babar ZUD，et al.Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD)：Systematic Review with Meta-analysis[J]．Sci Rep，2020，10(1)：5814.
[3]	令狐恩强，王宇菲，王潇潇．内镜下贲门缩窄术治疗胃食管反流病的报道一例[J/OL]．中华腔镜外科杂志(电子版)，2013，6(6)：468-469.
[4]	胡海清，张海静，靳春露，等．经口内镜下贲门缩窄术治疗胃食管反流病的临床研究[J]．中华消化内镜杂志，2019，36(8)：563-567.
[5]	曹会霞，熊英，韩静，等．经口内镜下贲门缩窄术和双倍剂量艾司奥美拉唑治疗难治性胃食管反流病的临床疗效对比[J/OL]．中华胃肠内镜电子杂志，2021，8(4)：171-175.
[6]	Li X，Zhang XB，Hu HQ，et al.Effect and Safety of Peroral Endoscopic Cardial Constriction for Gastroesophageal Reflux Disease[J]．Chinese Med J，2017，130(14)：1749-1750.
[7]	Hu HQ，Li HK，Xiong Y，et al.Peroral endoscopic cardial constriction in gastroesophageal reflux disease[J]．Medicine，2018，97(15)：e0169.
[8]	Shi C，Ma GZ，Ying L，et al.Efficacy and safety of endoscopic cardia peripheral tissue scar formation (ECSF) for the treatment of refractory gastroesophageal reflux disease：A systematic review with meta-analysis [J]．Medicine(Baltimore)，2024，103(10): e37062.
[9]	中华医学会消化病学分会胃肠动力学组，胃肠功能性疾病协作组，食管疾病协作组．中国胃食管反流病诊疗规范[J]．中华消化杂志，2023, 43(9): 588-598.
[10]	Akiyama J，Kuribayashi S，Baeg MK，et al.Current and future perspectives in the management of gastroesophageal reflux disease[J]. Ann N Y Acad Sci，2018, 434(1): 70-83.
[11]	Pohl H，Wrobel K，Bojarski C，et al.Risk factors in the development of esophageal adenocarcinoma[J]．Am J Gastroenterol，2013，108(2)：200- 207.
[12]	Trifan A，Stanciu C，Girleanu I，et al.Proton pump inhibitors therapy and risk of Clostridium difficile infection：Systematic review and meta-analysis[J]．World J Gastroenterol，2017，23(35)：6500-6515.
[13]	Liu J，Li X，Fan L，et al.Proton pump inhibitors therapy and risk of bone diseases：An update meta-analysis[J]．Life Sci，2019，218：213- 223.
[14]	Yang Y，George KC，Shang WF，et al.Proton-pump inhibitors use，and risk of acute kidney injury：a meta-analysis of observational studies[J]. Drug Des Devel Ther，2017，11: 1291-1299.
[15]	Katz PO，Dunbar KB，Schnoll-Sussman FH，et al.ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease[J]．Am J Gastroenterol，2022，117(1)：27-56.
[16]	Malfertheiner P，Kandulski A，Venerito M．Proton-pump inhibitors: understanding the complications and risks[J]．Nat Rev Gastroenterol Hepatol, 2017，14(12): 697-710.
[17]	Seo SI，Park CH，You SC，et al.Association between proton pump inhibitor use and gastric cancer：a population-based cohort study using two different types of nationwide databases in Korea[J]．Gut，2021, 70(11): 2066-2075.
[18]	Maret-Ouda J，Wahlin K，El-Serag HB，et al.Association Between Laparoscopic Antireflux Surgery and Recurrence of Gastroesophageal Reflux[J]．JAMA，2017, 318(10): 939-946.
[19]	Richter JE.Gastroesophageal reflux disease treatment：side effects and complications of fundoplication[J]．Clin Gastroenterol Hepatol，2013, 11(5): 465-471; quiz e39.
[20]	Ustaoglu A，Woodland P．Sensory Phenotype of the Oesophageal Mucosa in Gastro-Oesophageal Reflux Disease[J]．Int J Mol Sci，2023, 24(3): 2502.
[21]	Chua YC，Aziz Q．Perception of gastro-oesophageal reflux[J]．Best Pract Res Clin Gastroenterol，2010，24(6): 883-891.

患者基本特征	例数
性别
男	16(76.2)
女	5(23.8)
年龄
≤50岁	8(38.1)
>50岁	13(61.9)
体重指数
≤23.9 kg/m²	2(10.0)
>24.0 kg/m²	19(90.0)
吸烟史>10年	7(33.3)
饮酒史>10年	3(14.2)
症状持续时间
6个月~5年	13(61.9)
≥5年	8(38.1)
长期使用抗反流药物	11(52.4)
洛杉矶分级
LA-A级	5(23.8)
LA-B级	10(47.6)
LA-C级	6(28.6)
伴有食管裂孔疝	14(66.7)

患者基本特征	例数
性别
男	16(76.2)
女	5(23.8)
年龄
≤50岁	8(38.1)
>50岁	13(61.9)
体重指数
≤23.9 kg/m²	2(10.0)
>24.0 kg/m²	19(90.0)
吸烟史>10年	7(33.3)
饮酒史>10年	3(14.2)
症状持续时间
6个月~5年	13(61.9)
≥5年	8(38.1)
长期使用抗反流药物	11(52.4)
洛杉矶分级
LA-A级	5(23.8)
LA-B级	10(47.6)
LA-C级	6(28.6)
伴有食管裂孔疝	14(66.7)

术后疗效评估时间(月)	例数	临床基本治愈	症状显著改善	症状部分改善	治疗基本无效
3	21	11(52.4)	7(33.3)	2(9.5)	1(4.8)
6	21	13(61.9)	5(23.8)	2(9.5)	1(4.8)
12	16	11(68.8)	3(18.8)	2(12.5)	0(0)

术后疗效评估时间(月)	例数	临床基本治愈	症状显著改善	症状部分改善	治疗基本无效
3	21	11(52.4)	7(33.3)	2(9.5)	1(4.8)
6	21	13(61.9)	5(23.8)	2(9.5)	1(4.8)
12	16	11(68.8)	3(18.8)	2(12.5)	0(0)

术后时间(月)	例数	完全停药	偶尔服用	每天服用
3	21	7(33.3)	12(57.1)	2(9.5)
6	21	10(47.6)	10(47.6)	1(4.8)
12	16	12(75.0)	4(25.0)	0(0)

Please choose a citation manager

Content to export